Polycystic ovary syndrome in the pediatric population

Metabolic Syndrome and Related Disorders

Volumn 8, Issue 5, 2010, Pages 375-394

  Bremer, Andrew A ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIOL; ANDROSTENEDIONE; CHOLESTEROL; CORTISONE; CORTODOXONE; DROSPIRENONE PLUS ESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; EFLORNITHINE; ESTRADIOL; ESTRONE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; FINASTERIDE; FLUTAMIDE; GONADOTROPIN; HYDROCORTISONE; METFORMIN; OCTREOTIDE; ORNITHINE DECARBOXYLASE INHIBITOR; PIOGLITAZONE; PREGNENOLONE; PROGESTERONE; ROSIGLITAZONE; SPIRONOLACTONE; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA; TROGLITAZONE;

ADRENAL GLAND; APHASIA; BODY MASS; CHILD; CHILDHOOD DISEASE; DIABETES MELLITUS; DIET THERAPY; ESTHETIC SURGERY; FEMALE INFERTILITY; GENETIC PREDISPOSITION; GLUCOSE TOLERANCE; HIRSUTISM; HORMONE RELEASE; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; MENSTRUATION DISORDER; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PATIENT SAFETY; POSTNATAL CARE; PRIORITY JOURNAL; REVIEW; TRANSVAGINAL ECHOGRAPHY; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ANDROGENS; CHILD; COMORBIDITY; FEMALE; HIRSUTISM; HUMANS; HYPERANDROGENISM; INSULIN; MODELS, BIOLOGICAL; OVARY; PEDIATRICS; POLYCYSTIC OVARY SYNDROME;

EID: 77958134165     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2010.0039     Document Type: Review

References (274)

1. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-861.
2. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin En-docrinol Metab 2004;89:2745-2749.
3. Ehrmann D. Polycystic ovary syndrome. N Engl J Med 2005;352:1223-1236.
4. Franks S. Polycystic ovary syndrome in adolescents. Int J Obes (Lond) 2008;32:1035-1041.
5. Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA. Phenotypic variation in hyperandrogenic women influ¬ences the findings of abnormal metabolic and cardio¬vascular risk parameters. J Clin Endocrinol Metab 2005; 90:2545-2549.
6. Ehrmann DA, Liljenquist DR, Dasza K, Azziz R, Legro RS, Ghazzi MN, Group PTS. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syn¬drome. J Clin Endocrinol Metab 2006;91:48-53.
7. Coviello A, Legro R, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006;91:492-497.
8. Cussons AJ, Watts GF, Burke V, Shaw JE, Zimmet PZ, Stuckey BG. Cardiometabolic risk in polycystic ovary syn¬drome: A comparison of different approaches to defining the metabolic syndrome. Hum Reprod 2008;23:2352-2358.
9. Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syn¬drome during the reproductive life span. J Clin Endocrinol Metab 2005;90:4650-4658.
10. Dunaif A. Insulin resistance and the polycystic ovary syn¬drome: Mechanism and implications for pathogenesis. En-docr Rev 1997;18:774-800.
11. Dunaif A. Insulin action in the polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;28:341-359.
12. Book C-B, Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1999;84:3110-3116.
13. Venkatesan AM, Dunaif A, Corbould A. Insulin resistance in polycystic ovary syndrome: Progress and paradoxes. Recent Prog Horm Res 2001;56:295-308.
14. Diamanti-Kandarakis E, Xyrafis X, Boutzios G, Christakou C. Pancreatic beta-cells dysfunction in polycystic ovary syndrome. Panminerva Med 2008;50:315-325.
15. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF. Positions statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91: 4237-4245.
16. Franks S. Adult polycystic ovary syndrome begins in childhood. Best Pract Res Clin Endocrinol Metab 2002;16: 263-272.
17. Ibanez L, Diaz R, Lopez-Bermejo A, Marcos MV. Clinical spectrum of premature pubarche: Links to metabolic syn¬drome and ovarian hyperandrogenism. Rev Endocr Metab Disord 2009;10:63-76.
18. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In: Dunaif A, Givens JR, Haseltine F (eds). Polycystic Ovary Syndrome. Boston: Blackwell Scientific, 1992:377-384.
19. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
20. Diamanti-Kandarakis E, Panidis D. Unravelling the phe-notypic map of polycystic ovary syndrome (PCOS): A pro¬spective study of 634 women with PCOS. Clin Endocrinol 2007;67:735-742.
21. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF. The Androgen Excess and PCOS Society criteria for the polycystic ovary syn¬drome: The complete task force report. Fertil Steril 2009;91: 456-488.
22. Dewailly D, Catteau-Jonard S, Reyss AC, Leroy M, Pigny P. Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. J Clin Endocrinol Metab 2006;91:3922-3927.
23. Diaz A, Laufer MR, Breech LL. Menstruation in girls and adolescents: Using the menstrual cycle as a vital sign. Pediatrics 2006;118:2245-2250.
24. Southam AL, Richart RM. The prognosis for adolescents with menstrual abnormalities. Am J Obstet Gynecol 1966; 94:637-645.
25. Buggs C, Rosenfield RL. Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin North Am 2005;34: 677-705.
26. Goodman NF, Bledsoe MB, Cobin RH, Futterweit W, Goldzieher JW, Petak SM, Smith KD, Steinberger E. American Association of Clinical Endocrinologists medical guidelines for the clinical practice for the diagnosis and treatment of hyperandrogenic disorders. Endocr Pract 2001; 7:120-134.
27. Hannon TS, Janosky J, Arslanian SA. Longitudinal study of physiologic insulin resistance and metabolic changes of puberty. Pediatr Res 2006;60:759-763.
28. Moran A, Jacobs DR, Jr., Steinberger J, Steffen LM, Pankow JS, Hong CP, Sinaiko AR. Changes in insulin resistance and cardiovascular risk during adolescence: Establishment of differential risk in males and females. Circulation 2008; 117:2361-2368.
29. Moran A, Jacobs DR, Jr., Steinberger J, Hong CP, Prineas R, Luepker R, Sinaiko AR. Insulin resistance during puberty: Results from clamp studies in 357 children. Diabetes 1999;48:2039-2044.
30. van Hooff MH, Voorhorst FJ, Kaptein MB, Hirasing RA, Koppenaal C, Schoemaker J. Polycystic ovaries in adoles¬cents and the relationship with menstrual cycle patterns, luteinizing hormone, androgens, and insulin. Fertil Steril 2000;74:49-58.
31. Azziz R. Controversy in clinical endocrinology: Diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab 2006;91:781-785.
32. Blank SK, Helm KD, McCartney CR, Marshall JC. Poly-cystic ovary syndrome in adolescence. Ann NY Acad Sci 2008;1135:76-84.
33. Rosenfield RL. Clinical review: Identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:787-796.
34. Biro FM, Emans SJ. Whither PCOS? The challenges of es¬tablishing hyperandrogenism in adolescent girls. J Adolesc Health 2008;43:103-105.
35. Sultan C, Paris F. Clinical expression of polycystic ovary syndrome in adolescent girls. Fertil Steril 2006;86(Suppl 1):S6.
36. Legro R, Driscoll D, Strauss 3rd JF, Fox J, Dunaif A. Evi¬dence for a genetic basis for hyperandrogenism in poly-cystic ovary syndrome. Proc Natl Acad Sci USA 1998;95: 14956-1460.
37. Xita N, Georgiou I, Tsatsoulis A. The genetic basis of polycystic ovary syndrome. Eur J Endocrinol 2002;147: 717-725.
38. Nardo LG, Patchava S, Laing I. Polycystic ovary syndrome: Pathophysiology, molecular aspects and clinical implica¬tions. Panminerva Med 2008;50:267-278.
39. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome\a hypothesis. J Endocrinol 2002;174:1-5.
40. Franks S, McCarthy MI, Hardy K. Development of poly-cystic ovary syndrome: Involvement of genetic and envi¬ronmental factors. Int J Androl 2006;29:278-285.
41. Eisner JR, Dumesic DA, Kemnitz JW, Abbott DH. Timing of prenatal androgen excess determines differential impair¬ment in insulin secretion and action in adult female rhesus monkeys. J Clin Endocrinol Metab 2000;85:1206-1210.
42. Eisner JR, Barnett MA, Dumesic DA, Abbott DH. Ovarian hyperandrogenism in adult female rhesus monkeys ex¬posed to prenatal androgen excess. Fertil Steril 2002;77: 167-172.
43. Abbott DH, Barnett DK, Levine JE, Padmanabhan V, Dumesic DA, Jacoris S, Tarantal AF. Endocrine antecedents of polycystic ovary syndrome in fetal and infant prenatally androgenized female rhesus monkeys. Biol Reprod 2008;79: 154-163.
44. Abbott DH, Zhou R, Bird IM, Dumesic DA, Conley AJ. Fetal programming of adrenal androgen excess: lessons from a nonhuman primate model of polycystic ovary syn¬drome. Endocr Dev 2008;13:145-158.
45. Abbott DH, Tarantal AF, Dumesic DA. Fetal, infant, ado¬lescent and adult phenotypes of polycystic ovary syndrome in prenatally androgenized female rhesus monkeys. Am J Primatol 2009;71:1-9.
46. Barker DJ, Clark PM. Fetal undernutrition and disease in later life. Rev Reprod 1997;2:105-112.
47. Barker DJ. Maternal nutrition, fetal nutrition, and disease in later life. Nutrition 1997;13:807-813.
48. Miller WL. Molecular biology of steroid hormone synthesis. Endocr Rev 1988;9:295-318.
49. Barnes RB, Rosenfield RL, Burstein S, Ehrmann DA. Pitui¬tary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med 1989;320:559-565.
50. Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF, Sheikh Z. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 1992;327: 157-162.
51. Lachelin GC, Judd HL, Swanson SC, Hauck ME, Parker DC, Yen SS. Long term effects of nightly dexamethasone administration in patients with polycystic ovarian disease. J Clin Endocrinol Metab 1982;55:768-773.
52. Rittmaster RS, Thompson DL. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: The relative importance of the ovary and the adrenal in the pathogenesis of hirsutism. J Clin En-docrinol Metab 1990;70:1096-1102.
53. Nelson VL, Legro RS, Strauss JF, 3rd, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ova¬ries. Mol Endocrinol 1999;13:946-957.
54. Ibanez L, Potau N, Zampolli M, Prat N, Gussinye M, Saenger P, Vicens-Calvet E, Carrascosa A. Source localiza¬tion of androgen excess in adolescent girls. J Clin Endocrinol Metab 1994;79:1778-1784.
55. Moran C, Reyna R, Boots LS, Azziz R. Adrenocortical hyperresponsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgen excess. Fertil Steril 2004;81:126-131.
56. Kumar A, Woods KS, Bartolucci AA, Azziz R. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2005;62: 644-649.
57. Silfen ME, Denburg MR, Manibo AM, Lobo RA, Jaffe R, Ferin M, Levine LS, Oberfield SE. Early endocrine, meta¬bolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab 2003;88:4682-4688.
58. Fassnacht M, Schlenz N, Schneider SB, Wudy SA, Allolio B, Arlt W. Beyond adrenal and ovarian androgen generation: Increased peripheral 5a-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:2760-2766.
59. Chung BC, Picado-Leonard J, Haniu M, Bienkowski M, Hall PF, Shively JE, Miller WL. Cytochrome P450c17 (ste¬roid 17a-hydroxylase/17,20 lyase): Cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues. Proc Natl Acad Sci USA 1987;84: 407-411.
60. Nakajin S, Shively JE, Yuan PM, Hall PF. Microsomal cy-tochrome P-450 from neonatal pig testis: Two enzymatic activities (17a-hydroxylase and c17,20-lyase) associated with one protein. Biochemistry 1981;20:4037-4042.
61. Zuber MX, Simpson ER, Waterman MR. Expression of bovine 17a-hydroxylase cytochrome P-450 cDNA in non-steroidogenic (COS 1) cells. Science 1986;234:1258-1261.
62. Auchus RJ, Miller WL. Molecular modeling of human P450c17 (17a-hydroxylase/17,20-lyase): Insights into reac¬tion mechanisms and effects of mutations. Mol Endocrinol 1999;13:1169-1182.
63. Miller WL. Steroidogenic enzymes. Endocr Dev 2008; 13:1-18.
64. th ed. Philadelphia: WB Saunders, 2005:2263-2285.
65. Miller WL, Auchus RJ, Geller DH. The regulation of 17,20 lyase activity. Steroids 1997;62:133-142.
66. Wickenheisser JK, Quinn PG, Nelson VL, Legro RS, Stauss 3rd JF, McAllister JM. Differential activity of the cyto-chrome P450 17a-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and poly-cystic ovary syndrome theca cells. J Clin Endocrinol Metab 2000;85:2304-2311.
67. Jakimiuk AJ, Weitsman SR, Navab A, Magoffin DA. Luteinizing hormone receptor, steroidogenesis acute regu¬latory protein, and steroidogenic enzyme messenger ribo-nucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries. J Clin Endocrinol Metab 2001; 86:1318-1323.
68. Blank SK, McCartney CR, Chhabra S, Helm KD, Eagleson CA, Chang RJ, Marshall JC. Modulation of gonadotropin-releasing hormone pulse generator sensitivity to proges¬terone inhibition in hyperandrogenic adolescent girls\implications for regulation of pubertal maturation. J Clin Endocrinol Metab 2009;94:2360-2366.
69. Blank SK, McCartney CR, Helm KD, Marshall JC. Neu-roendocrine effects of androgens in adult polycystic ovary syndrome and female puberty. Semin Reprod Med 2007;25: 352-359.
70. Waldstreicher J, Santoro NF, Hall JE, Filicori M, Crowley WF, Jr. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: Indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab 1988;66:165-172.
71. Gross KM, Matsumoto AM, Bremner WJ. Differential con¬trol of luteinizing hormone and follicle-stimulating hor¬mone secretion by luteinizing hormone-releasing hormone pulse frequency in man. J Clin Endocrinol Metab 1987;64: 675-680.
72. Haisenleder DJ, Dalkin AC, Ortolano GA, Marshall JC, Shupnik MA. A pulsatile gonadotropin-releasing hormone stimulus is required to increase transcription of the gonadotropin subunit genes: evidence for differential regulation of transcription by pulse frequency in vivo. En¬docrinology 1991;128:509-517.
73. Ciccone NA, Kaiser UB. The biology of gonadotroph regulation. Curr Opin Endocrinol Diabetes Obes 2009;16: 321-327.
74. Taylor AE, McCourt B, Martin KA, Anderson EJ, Adams JM, Schoenfeld D, Hall JE. Determinants of abnormal go-nadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:2248-2256.
75. Filicori M, Santoro N, Merriam GR, Crowley WF, Jr. Characterization of the physiological pattern of episodic gonadotropin secretion throughout the human menstrual cycle. J Clin Endocrinol Metab 1986;62:1136-1144.
76. Rasmussen DD, Gambacciani M, Swartz W, Tueros VS, Yen SS. Pulsatile gonadotropin-releasing hormone release from the human mediobasal hypothalamus in vitro: opiate receptor-mediated suppression. Neuroendocrinology 1989;49: 150-156.
77. Rossmanith WG, Liu CH, Laughlin GA, Mortola JF, Suh BY, Yen SS. Relative changes in LH pulsatility during the menstrual cycle: Using data from hypogonadal women as a reference point. Clin Endocrinol (Oxf) 1990;32:647-660.
78. Gill S, Lavoie HB, Bo-Abbas Y, Hall JE. Negative feedback effects of gonadal steroids are preserved with aging in postmenopausal women. J Clin Endocrinol Metab 2002;87: 2297-2302.
79. Nippoldt TB, Reame NE, Kelch RP, Marshall JC. The roles of estradiol and progesterone in decreasing luteinizing hormone pulse frequency in the luteal phase of the men¬strual cycle. J Clin Endocrinol Metab 1989;69:67-76.
80. Romano GJ, Krust A, Pfaff DW. Expression and estrogen regulation of progesterone receptor mRNA in neurons of the mediobasal hypothalamus: An in situ hybridization study. Mol Endocrinol 1989;3:1295-1300.
81. Soules MR, Steiner RA, Clifton DK, Cohen NL, Aksel S, Bremner WJ. Progesterone modulation of pulsatile lutei-nizing hormone secretion in normal women. J Clin En-docrinol Metab 1984;58:378-383.
82. Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS, Marshall JC. Polycystic ovarian syndrome: Evidence that flutamide restores sensitivity of the gonad-otropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 2000;85:4047-4052.
83. Goodarzi MO, Guo X, Yildiz BO, Stanczyk FZ, Azziz R. Correlation of adrenocorticotropin steroid levels between women with polycystic ovary syndrome and their sisters. Am J Obstet Gynecol 2007;196:398 e1-e5.
84. Baillargeon JP, Carpentier AC. Brothers of women with polycystic ovary syndrome are characterised by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects. Diabetologia 2007;50:2424-2432.
85. Franks S, Webber LJ, Goh M, Valentine A, White DM, Conway GS, Wiltshire S, McCarthy MI. Ovarian morphol¬ogy is a marker of heritable biochemical traits in sisters with polycystic ovaries. J Clin Endocrinol Metab 2008; 93:3396-3402.
86. Sam S, Coviello AD, Sung YA, Legro RS, Dunaif A. Me¬tabolic phenotype in the brothers of women with polycystic ovary syndrome. Diabetes Care 2008;31:1237-1241.
87. Kent SC, Gnatuk CL, Kunselman AR, Demers LM, Lee PA, Legro RS. Hyperandrogenism and hyperinsulinism in children of women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 2008;93: 1662-1669.
88. Nam Menke M, Strauss JF 3rd. Genetics of polycystic ovarian syndrome. Clin Obstet Gynecol 2007;50:188-204.
89. Urbanek M. The genetics of the polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab 2007;3:103-111.
90. Unluturk U, Harmanci A, Kocaefe C, Yildiz BO. The ge¬netic basis of the polycystic ovary syndrome: A literature review including discussion of PPAR-gamma. PPAR Res 2007;2007:49109.
91. Tucci S, Futterweit W, Concepcion ES, Greenberg DA, Villanueva R, Davies TF, Tomer Y. Evidence for association of polycystic ovary syndrome in caucasian women with a marker at the insulin receptor gene locus. J Clin Endocrinol Metab 2001;86:446-449.
92. Urbanek M, Woodroffe A, Ewens KG, Diamanti-Kandar-akis E, Legro RS, Strauss JF 3rd, Dunaif A, Spielman RS. Candidate gene region for polycystic ovary syndrome on chromosome 19p13.2. J Clin Endocrinol Metab 2005;90: 6623-6629.
93. Stewart DR, Dombroski BA, Urbanek M, Ankener W, Ewens KG, Wood JR, Legro RS, Strauss JF 3rd, Dunaif A, Spielman RS. Fine mapping of genetic susceptibility to polycystic ovary syndrome on chromosome 19p13.2 and tests for regulatory activity. J Clin Endocrinol Metab 2006; 91:4112-4117.
94. Urbanek M, Sam S, Legro RS, Dunaif A. Identification of a polycystic ovary syndrome susceptibility variant in fi-brillin-3 and association with a metabolic phenotype. J Clin Endocrinol Metab 2007;92:4191-4198.
95. Matzuk MM. Revelations of ovarian follicle biology from gene knockout mice. Mol Cell Endocrinol 2000;163:61-66.
96. Xita N, Georgiou I, Lazaros L, Psofaki V, Kolios G, Tsatsoulis A. The role of sex hormone-binding globulin and androgen receptor gene variants in the development of polycystic ovary syndrome. Hum Reprod 2008;23: 693-698.
97. Xita N, Georgiou I, Lazaros L, Psofaki V, Kolios G, Tsat-soulis A. The synergistic effect of sex hormone-binding globulin and aromatase genes on polycystic ovary syn¬drome phenotype. Eur J Endocrinol 2008;158:861-865.
98. Jones MR, Mathur R, Cui J, Guo X, Azziz R, Goodarzi MO. Independent confirmation of association between metabolic phenotypes of polycystic ovary syndrome and variation in the type 6 17beta-hydroxysteroid dehydrogenase gene. J Clin Endocrinol Metab 2009;94: 5034-5038.
99. Xita N, Tsatsoulis A. Review: fetal programming of poly-cystic ovary syndrome by androgen excess: Evidence from experimental, clinical, and genetic association studies. J Clin Endocrinol Metab 2006;91:1660-1666.
100. Zhou R, Bird IM, Dumesic DA, Abbott DH. Adrenal hy-perandrogenism is induced by fetal androgen excess in a rhesus monkey model of polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:6630-6637.
101. Abbott DH, Barnett DK, Bruns CM, Dumesic DA. Andro-gen excess fetal programming of female reproduction: A developmental aetiology for polycystic ovary syndrome? Hum Reprod Update 2005;11:357-374.
102. Abbott DH, Bird IM. Nonhuman primates as models for human adrenal androgen production: function and dys¬function. Rev Endocr Metab Disord 2009;10:33-42.
103. Sir-Petermann T, Maliqueo M, Angel B, Lara HE, Perez-Bravo F, Recabarren SE. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: pos¬sible implications in prenatal androgenization. Hum Reprod 2002;17:2573-2579.
104. Carlsen SM, Jacobsen G, Romundstad P. Maternal testos¬terone levels during pregnancy are associated with off¬spring size at birth. Eur J Endocrinol 2006;155:365-370.
105. Sir-Petermann T, Hitchsfeld C, Maliqueo M, Codner E, Echiburu B, Gazitua R, Recabarren S, Cassorla F. Birth weight in offspring of mothers with polycystic ovarian syndrome. Hum Reprod 2005;20:2122-2126.
106. McClamrock HD, Adashi EY. Gestational hyperandrogen-ism. Fertil Steril 1992;57:257-274.
107. Cole B, Hensinger K, Maciel GA, Chang RJ, Erickson GF. Human fetal ovary development involves the spatiotem-poral expression of p450c17 protein. J Clin Endocrinol Metab 2006;91:3654-3661.
108. Barnes RB, Rosenfield RL, Ehrmann DA, Cara JF, Cuttler L, Levitsky LL, Rosenthal IM. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: Evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab 1994;79:1328-1333.
109. Demissie M, Lazic M, Foecking EM, Aird F, Dunaif A, Levine JE. Transient prenatal androgen exposure produces metabolic syndrome in adult female rats. Am J Physiol En-docrinol Metab 2008;295:E262-E268.
110. Diamanti-Kandarakis E, Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Hum Reprod Update 2005;11:631-643.
111. Ibanez L, Potau N, Francois I, de Zegher F. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogen-ism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab 1998;83:3558-3562.
112. Miller WL. Androgen synthesis in adrenarche. Rev Endocr Metab Disord 2009;10:3-17.
113. Ibanez L, Potau N, Zampolli M, Rique S, Saenger P, Car-rascosa A. Hyperinsulinemia and decreased insulin-like growth factor-binding protein-1 are common features in prepubertal and pubertal girls with a history of premature pubarche. J Clin Endocrinol Metab 1997;82:2283-2288.
114. Ibanez L, Dimartino-Nardi J, Potau N, Saenger P. Pre¬mature adrenarche\normal variant or forerunner of adult disease? Endocr Rev 2000;21:671-696.
115. Parker LN, Lifrak ET, Odell WD. A 60,000 molecular weight human pituitary glycopeptide stimulates adrenal androgen secretion. Endocrinology 1983;113:2092-2096.
116. Mellon SH, Shively JE, Miller WL. Human proopiomela-nocortin-(79-96), a proposed androgen stimulatory hor¬mone, does not affect steroidogenesis in cultured human fetal adrenal cells. J Clin Endocrinol Metab 1991;72:19-22.
117. Dickerman Z, Grant DR, Faiman C, Winter JS. Intraadrenal steroid concentrations in man: Zonal differences and de¬velopmental changes. J Clin Endocrinol Metab 1984;59:1031-1036.
118. Zhang L-H, Rodriguez H, Ohno S, Miller WL. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: Implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci USA 1995;92:10619-10623.
119. Ibanez L, Potau N, Marcos MV, de Zegher F. Corticotropin-releasing hormone as adrenal androgen secretagogue. Pediatr Res 1999;46:351-353.
120. Ibanez L, Potau N, Marcos MV, de Zegher F. Corticotropin-releasing hormone: a potent androgen secretagogue in girls with hyperandrogenism after precocious pubarche. J Clin Endocrinol Metab 1999;84:4602-4606.
121. Ibanez L, Lopez-Bermejo A, Callejo J, Torres A, Cabre S, Dunger D, de Zegher F. Polycystic ovaries in nonobese adolescents and young women with ovarian androgen excess: relation to prenatal growth. J Clin Endocrinol Metab 2008;93:196-199.
122. Ibanez L, Valls C, Potau N, Marcos MV, de Zegher F. Polycystic ovary syndrome after precocious pubarche: Ontogeny of the low-birthweight effect. Clin Endocrinol (Oxf) 2001;55:667-672.
123. Ibanez L, Potau N, Virdis R, Zampolli M, Terzi C, Cus-sinye M, Carrascosa A, Vicens-Calvet E. Postpubertal outcome in girls diagnosed of premature pubarche during childhood: Increased frequency of functional ovarian hy-perandrogenism. J Clin Endocrinol Metab 1993;76:1599-1603.
124. Diamanti-Kandarakis E, Christakou C, Kandarakis H. Polycystic ovarian syndrome: the commonest cause of hy-perandrogenemia in women as a risk factor for metabolic syndrome. Minerva Endocrinol 2007;32:35-47.
125. Martha PM, Jr., Rogol AD, Veldhuis JD, Kerrigan JR, Goodman DW, Blizzard RM. Alterations in the pulsatile properties of circulating growth hormone concentrations during puberty in boys. J Clin Endocrinol Metab 1989;69:563-570.
126. Caprio S, Plewe G, Diamond MP, Simonson DC, Boulware SD, Sherwin RS, Tamborlane WV. Increased insulin secre¬tion in puberty: A compensatory response to reductions in insulin sensitivity. J Pediatr 1989;114:963-967.
127. de Zegher F, Lopez-Bermejo A, Ibanez L. Adipose tissue expandability and the early origins of PCOS. Trends En-docrinol Metab 2009;20:418-423.
128. Virtue S, Vidal-Puig A. It's not how fat you are, it's what you do with it that counts. PLoS Biol 2008;6:e237.
129. Garg A. Adipose tissue dysfunction in obesity and lipo-dystrophy. Clin Cornerstone 2006;8 Suppl 4:S7-S13.
130. Gray SL, Vidal-Puig AJ. Adipose tissue expandability in the maintenance of metabolic homeostasis. Nutr Rev 2007;65: S7-S12.
131. Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome\an allostatic perspective. Biochim Biophys Acta 2010;1801:338-349.
132. Christakou CD, Diamanti-Kandarakis E. Role of androgen excess on metabolic aberrations and cardiovascular risk in women with polycystic ovary syndrome. Womens Health (Lond Engl) 2008;4:583-594.
133. Mayes JS, Watson GH. Direct effects of sex steroid hormones on adipose tissues and obesity. Obes Rev 2004;5: 197-216.
134. Anderson LA, McTernan PG, Harte AL, Barnett AH, Kumar S. The regulation of HSL and LPL expression by DHT and flutamide in human subcutaneous adipose tissue. Diabetes Obes Metab 2002;4:209-213.
135. Arner P. Effects of testosterone on fat cell lipolysis. Species differences and possible role in polycystic ovarian syn¬drome. Biochimie 2005;87:39-43.
136. McInnes KJ, Corbould A, Simpson ER, Jones ME. Regula¬tion of adenosine 5-monophosphate-activated protein ki-nase and lipogenesis by androgens contributes to visceral obesity in an estrogen-deficient state. Endocrinology 2006; 147:5907-5913.
137. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003;24:183-217.
138. Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP. Pathophysiology and types of dysli-pidemia in PCOS. Trends Endocrinol Metab 2007;18: 280-285.
139. Langer C, Gansz B, Goepfert C, Engel T, Uehara Y, von Dehn G, Jansen H, Assmann G, von Eckardstein A. Tes¬tosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun 2002;296:1051-1057.
140. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD. Polycystic ovary syndrome is as¬sociated with endothelial dysfunction. Circulation 2001;103:1410-1415.
141. Kravariti M, Naka KK, Kalantaridou SN, Kazakos N, Kat-souras CS, Makrigiannakis A, Paraskevaidis EA, Chrousos GP, Tsatsoulis A, Michalis LK. Predictors of endothelial dysfunction in young women with polycystic ovary syn¬drome. J Clin Endocrinol Metab 2005;90:5088-5095.
142. Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF. Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. Hum Reprod 2007;22:3197-3203.
143. Chen MJ, Yang WS, Yang JH, Chen CL, Ho HN, Yang YS. Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome. Hypertension 2007;49:1442-1447.
144. Luque-Ramirez M, Alvarez-Blasco F, Mendieta-Azcona C, Botella-Carretero JI, Escobar-Morreale HF. Obesity is the major determinant of the abnormalities in blood pressure found in young women with the polycystic ovary syn¬drome. J Clin Endocrinol Metab 2007;92:2141-2148.
145. Chen YF, Naftilan AJ, Oparil S. Androgen-dependent an-giotensinogen and renin messenger RNA expression in hypertensive rats. Hypertension 1992;19:456-463.
146. Quan A, Chakravarty S, Chen JK, Chen JC, Loleh S, Saini N, Harris RC, Capdevila J, Quigley R. Androgens augment proximal tubule transport. Am J Physiol Renal Physiol 2004; 287:F452-F459.
147. Quinkler M, Bujalska IJ, Kaur K, Onyimba CU, Buhner S, Allolio B, Hughes SV, Hewison M, Stewart PM. Androgen receptor-mediated regulation of the alpha-subunit of the epithelial sodium channel in human kidney. Hypertension 2005;46:787-798.
148. Diamanti-Kandarakis E, Paterakis T, Kandarakis HA. Indices of low-grade inflammation in polycystic ovary syndrome. Ann NY Acad Sci 2006;1092:175-186.
149. Diamanti-Kandarakis E, Alexandraki K, Piperi C, Proto-gerou A, Katsikis I, Paterakis T, Lekakis J, Panidis D. Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur J Clin Invest 2006;36: 691-697.
150. Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003;80:123-127.
151. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983;57:356-359.
152. Jialal I, Naiker P, Reddi K, Moodley J, Joubert SM. Evidence for insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1987;64:1066-1069.
153. Burghen GA, Givens JR, Kitabchi AE. Correlation of hy-perandrogenism with hyperinsulinism in polycystic ovar¬ian disease. J Clin Endocrinol Metab 1980;50:113-116.
154. Nagamani M, Van Dinh T, Kelver ME. Hyperinsulinemia in hyperthecosis of the ovaries. Am J Obstet Gynecol 1986; 154:384-349.
155. Geffner ME, Kaplan SA, Bersch N, Golde DW, Landaw EM, Chang RJ. Persistence of insulin resistance in polycystic ovarian disease after inhibition of ovarian steroid secretion. Fertil Steril 1986;45:327-333.
156. Dunaif A, Green G, Futterweit W, Dobrjansky A. Sup¬pression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syn¬drome. J Clin Endocrinol Metab 1990;70:699-704.
157. Diamanti-Kandarakis E, Mitrakou A, Hennes MM, Plata-nissiotis D, Kaklas N, Spina J, Georgiadou E, Hoffmann RG, Kissebah AH, Raptis S. Insulin sensitivity and anti-androgenic therapy in women with polycystic ovary syn¬drome. Metabolism 1995;44:525-531.
158. Diamond MP, Grainger D, Diamond MC, Sherwin RS, Defronzo RA. Effects of methyltestosterone and insulin secretion and sensitivity in women. J Clin Endocrinol Metab 1998;83:4420-4425.
159. Speiser PW, Serrat J, New MI, Gertner JM. Insulin insen-sitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 1992; 75:1421-1424.
160. Barbieri RL, Makris A, Ryan KJ. Insulin stimulates andro-gen accumulation in incubations of human ovarian stroma and theca. Obstet Gynecol 1984;64:73S-80S.
161. Cara JF, Rosenfield RL. Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. En¬docrinology 1988;123:733-739.
162. Hernandez ER, Resnick CE, Holtzclaw WD, Payne DW, Adashi EY. Insulin as a regulator of androgen biosynthesis by cultured rat ovarian cells: cellular mechanism(s) un¬derlying physiological and pharmacological hormonal ac¬tions. Endocrinology 1988;122:2034-2043.
163. Moghetti P, Castello R, Nigri C, Tosi F, Spiazzi GG, Brun E, Balducci R, Toscano V, Muggeo M. Insulin infusion am¬plifies 17 alpha- hydroxycorticosteroid intermediates re¬sponse to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J Clin Endocrinol Metab 1996;81:881-886.
164. Adashi EY, Hsueh AJ, Yen SS. Insulin enhancement of lu-teinizing hormone
165. Soldani R, Cagnacci A, Yen SS. Insulin, insulin-like growth factor I (IGF-I) and IGF-II enhance basal and gonadotro-phin-releasing hormone-stimulated luteinizing hormone release from rat anterior pituitary cells in vitro. Eur J En-docrinol 1994;131:641-645.
166. Dunkel L, Sorva R, Voutilainen R. Low levels of sex hor¬mone-binding globulin in obese children. J Pediatr 1985; 107:95-97.
167. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991;72:83-89.
168. Suikkari AM, Koivisto VA, Rutanen EM, Yki-Jarvinen H, Karonen SL, Seppala M. Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J Clin Endocrinol Metab 1988;66:266-272.
169. Lee PD, Conover CA, Powell DR. Regulation and function of insulin-like growth factor-binding protein-1. Proc Soc Exp Biol Med 1993;204:4-29.
170. LeRoith D, McGuinness M, Shemer J, Stannard B, Lanau F, Faria TN, Kato H, Werner H, Adamo M, Robers CTJ. Insulin-like growth factors. Biol Signals 1992;1: 173-181.
171. Franks S, Gilling-Smith C, Watson H, Willis D. Insulin ac¬tion in the normal and polycystic ovary. Endocrinol Metab Clin North Am 1999;28:361-378.
172. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992;41:1257-1266.
173. Conway GS, Avey C, Rumsby G. The tyrosine kinase do¬main of the insulin receptor gene is normal in women with hyperinsulinaemia and polycystic ovary syndrome. Hum Reprod 1994;9:1681-1683.
174. Talbot JA, Bicknell EJ, Rajkhowa M, Krook A, O'Rahilly S, Clayton RN. Molecular scanning of the insulin receptor gene in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:1979-1983.
175. Ciaraldi TP, el-Roeiy A, Madar Z, Reichart D, Olefsky JM, Yen SS. Cellular mechanisms of insulin resistance in poly-cystic ovary syndrome. J Clin Endocrinol Metab 1992;75: 577-583.
176. Dunaif A, Xia J, Book C-B, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibro-blasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995;96:801-810.
177. Bollage GE, Roth RA, Beaudoin J, Mochly-Rosen D, Doshland DEJ. Protein kinase C directly phosphorylates the insulin receptor in vitro and reduces its protein-tyrosine kinase activity. Proc Natl Acad Sci USA 1986;83:5822-5824.
178. Stadtmauer L, Rosen OM. Increasing the cAMP content of IM-9 cells alters the phosphorylation state and protein kinase activity of the insulin receptor. J Biol Chem 1986; 261:3402-3407.
179. Takayama S, White MF, Kahn CR. Phorbol ester-induced serine phosphorylation of the insulin receptor decreases its tyrosine kinase activity. J Biol Chem 1988;263:3440-3447.
180. Chin JE, Dickens M, Tavare JM, Roth RA. Overexpression of protein kinse C isoenzymes a, bI, g, and e in cells overexpressing the insulin receptor. Effects on recep¬tor phosphorylation and signaling. J Biol Chem 1993;268: 6338-6347.
181. Li M, Youngren JF, Dunaif A, Goldfine ID, Maddux BA, Zhang BB, Evans JL. Decreased insulin receptor (IR) au-tophosphorylation in fibroblasts from patients with PCOS: Effects of serine kinase inhibitors and IR activators. J Clin Endocrinol Metab 2002;87:4088-4093.
182. Guo H, Damuni Z. Autophosphorylation-activated protein kinase phosphorylates and inactivates protein phosphatase 2A. Proc Natl Acad Sci USA 1993;90:2500-2504.
183. Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H, Zick Y. A molecular basis for insulin resistance. J Biol Chem 1997;272:29911-9918.
184. Pirola L, Johnston AM, Obberghen EV. Modulation of in¬sulin action. Diabetologia 2004;47:170-184.
185. Liberman Z, Eldar-Finkelman H. Serine 332 phosphoryla-tion of insulin receptor substrate-1 by glycogen synthase kinase-3 attenuates insulin signaling. J Biol Chem 2005; 280:4422-4428.
186. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, Slezak LA, Andersen DK, Hundal RS, Rothman DL, Petersen KF, Shulman GI. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinosi-tol 3-kinase activity. J Clin Invest 1999;103:253-259.
187. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Speigelman BM. IRS-1-mediated inhibition of insulin re¬ceptor tyrosine kinase activity in TNF-a-and obesity-in¬duced insulin resistance. Science 1996;271:665-668.
188. Holte J, Bergh T, Berne C, Lithell H. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: Relation to anthropometric, endocrine and metabolic vari¬ables. Clin Endocrinol 1994;41:463-471.
189. Robinson S, Henderson AD, Gelding SV, Kiddy D, Nith-thyananthan R, Bush A, Richmond W, Johnston DG, Franks S. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol 1996;44: 277-284.
190. Naz RK, Thurston D, Santoro N. Circulating tumor necrosis factor (TNF)-a in normally cycling women and patients with premature ovarian failure and polycystic ovaries. Am J Reprod Immunol 1995;34:170-175.
191. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Inflammatory cy-tokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003;52:812-817.
192. Ciaraldi TP, Carter L, Nikoulina S, Mudaliar S, McClain DA, Henry RR. Glucosamine regulation of glucose metab¬olism in cultured human skeletal muscle cells: divergent effects on glucose transport/phosphorylation and glycogen synthase in non-diabetic and type 2 diabetic subjects. Endocrinology 1999;140:3971-3980.
193. Previs SF, Withers DJ, Ren JM, White MF, Shulman GI. Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism. J Biol Chem 2000; 275:38990-38994.
194. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw 3rd EB, Kaestner KH, Bartolomei MS, Shulman GI, Birn-baum MJ. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBb). Science 2001;292:1728-1731.
195. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-1174.
196. Poretsky L. On the paradox of insulin-induced hyperan-drogenism in insulin-resistant states. Endocr Rev 1991; 12:3-13.
197. Taylor SI. Molecular mechanisms of insulin resistance. Lessons learned from patients with mutations in the insu¬lin-receptor gene. Diabetes 1992;41:1473-1490.
198. Willis D, Franks S. Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the in¬sulin receptor and not the type-I insulin-like growth factor receptor. J Clin Endocrinol Metab 1995;80:3788-3790.
199. Corbould A, Zhao H, Mirzoeva S, Aird F, Dunaif A. En¬hanced mitogenic signaling in skeletal muscle of women with polycystic ovary syndrome. Diabetes 2006;55:751-759.
200. Lin Y, Fridstrom M, Hillensjo T. Insulin stimulation of lactate accumulation in isolated human granulosa-luteal cells: A comparison between normal and polycystic ova¬ries. Hum Reprod 1997;12:2469-2472.
201. Fedorcsak P, Storeng R, Dale PO, Tanbo T, Abyholm T. Impaired insulin action on granulosa-lutein cells in women with polycystic ovary syndrome and insulin resistance. Gynecol Endocrinol 2000;14:327-336.
202. Rice S, Christoforidis N, Gadd C, Nikolaou D, Seyani L, Donaldson A, Margara R, Hardy K, Franks S. Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum Reprod 2005;20:373-381.
203. Bremer AA, Miller WL. The serine phosphorylation hy¬pothesis of polycystic ovary syndrome: A unifying mech¬anism for hyperandrogenemia and insulin resistance. Fertil Steril 2008;89:1039-1048.
204. Diamanti-Kandarakis E, Christakou C, Palioura E, Kan-daraki E, Livadas S. Does polycystic ovary syndrome start in childhood? Pediatr Endocrinol Rev 2008;5:904-911.
205. O'Brien RF, Emans SJ. Polycystic ovary syndrome in ado¬lescents. J Pediatr Adolesc Gynecol 2008;21:119-128.
206. Dunaif A, Mandeli J, Fluhr H, Dobrjansky A. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome. J Clin Endocrinol Metab 1988;66:131-139.
207. Ciampelli M, Fulghesu AM, Cucinelli F, Pavone V, Ron-sisvalle E, Guido M, Caruso A, Lanzone A. Impact of in¬sulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism 1999;48: 167-172.
208. Moran C, Renteria JL, Moran S, Herrera J, Gonzalez S, Bermudez JA. Obesity differentially affects serum levels of androstenedione and testosterone in polycystic ovary syn¬drome. Fertil Steril 2008;90:2310-2317.
209. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 2004;291:2847-2850.
210. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin En-docrinol Metab 2002;87:1017-1023.
211. Albrecht L, Styne D. Laboratory testing of gonadal steroids in children. Pediatr Endocrinol Rev 2007;5(Suppl 1):599-607.
212. Nisenblat V, Norman RJ. Androgens and polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes 2009;16: 224-231.
213. Sir-Petermann T, Maliqueo M, Codner E, Echiburu B, Crisosto N, Perez V, Perez-Bravo F, Cassorla F. Early metabolic derangements in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92: 4637-4642.
214. Chang RJ, Coffler MS. Polycystic ovary syndrome: early detection in the adolescent. Clin Obstet Gynecol 2007;50: 178-187.
215. Giallauria F, Palomba S, Vigorito C, Tafuri MG, Colao A, Lombardi G, Orio F. Androgens in polycystic ovary syn¬drome: The role of exercise and diet. Semin Reprod Med 2009;27:306-315.
216. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, Franks S. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992;36:105-111.
217. Clark AM, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X, Norman RJ. Weight loss results in significant improvement in pregnancy and ovulation rates in anovu-latory obese women. Hum Reprod 1995;10:2705-2712.
218. Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995;80:2586-2593.
219. Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obese infertile women results in im¬provement in reproductive outcome for all forms of fertility treatment. Hum Reprod 1998;13:1502-1505.
220. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: Role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999;84: 1470-1474.
221. Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G. Overweight and obese anovulatory patients with polycystic ovaries: Parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod 2003;18:1928-1932.
222. Moran LJ, Noakes M, Clifton PM, Tomlinson L, Galletly C, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88:812-819.
223. Homburg R, Lambalk CB. Polycystic ovary syndrome in adolescence\a therapeutic conundrum. Hum Reprod 2004; 19:1039-1042.
224. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults\The Evidence Report. National Institutes of Health. Obes Res 1998; 6(Suppl 2):51S-209S.
225. Ludwig DS, Peterson KE, Gortmaker SL. Relation between consumption of sugar-sweetened drinks and childhood obesity: A prospective, observational analysis. Lancet 2001; 357:505-508.
226. Bray GA, Nielsen SJ, Popkin BM. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr 2004;79:537-543.
227. Mrdjenovic G, Levitsky DA. Nutritional and energetic consequences of sweetened drink consumption in 6-to 13-year-old children. J Pediatr 2003;142:604-610.
228. Johnson L, Mander AP, Jones LR, Emmett PM, Jebb SA. Is sugar-sweetened beverage consumption associated with increased fatness in children? Nutrition 2007;23:557-563.
229. Bremer AA, Auinger P, Byrd RS. Relationship between insulin resistance-associated metabolic parameters and an-thropometric measurements with sugar-sweetened bever¬age intake and physical activity levels in US adolescents: Findings from the 1999-2004 National Health and Nutri¬tion Examination Survey. Arch Pediatr Adolesc Med 2009; 163:328-335.
230. Pate RR, Pratt M, Blair SN, Haskell WL, Macera CA, Bouchard C, Buchner D, Ettinger W, Heath GW, King AC, Kriska A, Leon AS; Marcus BH, Morris J, Paffenbarger RS Jr, Patrick K, Pollock ML, Rippe JM, Sallis J, Wilmore JH. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 1995; 273:402-407.
231. Venables MC, Jeukendrup AE. Endurance training and obesity: Effect on substrate metabolism and insulin sensi¬tivity. Med Sci Sports Exerc 2008;40:495-502.
232. Ren JM, Semenkovich CF, Gulve EA, Gao J, Holloszy JO. Exercise induces rapid increases in GLUT4 expression, glucose transport capacity, and insulin-stimulated gly-cogen storage in muscle. J Biol Chem 1994;269:14396- 14401.
233. Perseghin G, Price TB, Petersen KF, Roden M, Cline GW, Gerow K, Rothman DL, Shulman GI. Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. N Engl J Med 1996;335:1357-1362.
234. Berlan ED, Emans SJ. Managing polycystic ovary syndrome in adolescent patients. J Pediatr Adolesc Gynecol 2009;22: 137-140.
235. Guttmann-Bauman I. Approach to adolescent polycystic ovary syndrome (PCOS) in the pediatric endocrine com¬munity in the U.S.A. J Pediatr Endocrinol Metab 2005;18: 499-506.
236. Korytkowski MT, Mokan M, Horwitz MJ, Berga SL. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995; 80:3327-3334.
237. Hillard PJ. Oral contraceptives and the management of hyperandrogenism-polycystic ovary syndrome in adoles¬cents. Endocrinol Metab Clin North Am 2005;34:707-723.
238. Thorneycroft IH, Stanczyk FZ, Bradshaw KD, Ballagh SA, Nichols M, Weber ME. Effect of low-dose oral contracep¬tives on Hillard PJ. Oral contraceptives and the manage¬ment of hyperandrogenism-polycystic ovary syndrome in adolescents androgenic markers and acne. Contraception 1999;60:255-262.
239. Mastorakos G, Koliopoulos C, Deligeoroglou E, Diamanti-Kandarakis E, Creatsas G. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in ado¬lescents with polycystic ovary syndrome. Fertil Steril 2006; 85:420-427.
240. Pfeifer SM, Kives S. Polycystic ovary syndrome in the ad¬olescent. Obstet Gynecol Clin North Am 2009;36:129-152.
241. Ibanez L, Potau N, Marcos MV, de Zegher F. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipide-mia, and hyperinsulinism in nonobese, adolescent girls: Effect of flutamide. J Clin Endocrinol Metab 2000;85:3251-3255.
242. Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone F, Caputo M, Muggeo M, Castello R. Comparison of spir-onolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: A randomized, double blind, pla¬cebo-controlled trial. J Clin Endocrinol Metab 2000;85:89-94.
243. Practice Committee of American Society for Reproductive Medicine. Use of insulin-sensitizing agents in the treat¬ment of polycystic ovary syndrome. Fertil Steril 2008;90: S69-S73.
244. Katsiki N, Georgiadou E, Hatzitolios AI. The role of insu¬lin- sensitizing agents in the treatment of polycystic ovary syndrome. Drugs 2009;69:1417-1431.
245. Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 2009; 30:1-50.
246. Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN. Metformin: An old medication of new fashion: Evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol 2010;162:193-212.
247. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998;338:867-872.
248. La Marca A, Artensio AC, Stabile G, Volpe A. Metformin treatment of PCOS during adolescence and the repro¬ductive period. Eur J Obstet Gynecol Reprod Biol 2005; 121:3-7.
249. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the in¬cidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
250. Ibanez L, Ferrer A, Ong K, Amin R, Dunger D, de Zegher F. Insulin sensitization early after menarche prevents pro¬gression from precocious pubarche to polycystic ovary syndrome. J Pediatr 2004;144:23-29.
251. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syn¬drome and impaired glucose tolerance: Amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin En-docrinol Metab 2002;87:1555-1559.
252. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health 2001;29:160-169.
253. Ibanez L, Valls C, Ferrer A, Marcos MV, Rodriguez-Hierro F, de Zegher F. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogen-ism. J Clin Endocrinol Metab 2001;86:3595-3598.
254. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001;107:E55.
255. Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normo-glycemic morbidly obese adolescents. Metabolism 2001;50: 1457-1461.
256. Bridger T, MacDonald S, Baltzer F, Rodd C. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med 2006; 160:241-246.
257. De Leo V, Musacchio MC, Morgante G, Piomboni P, Pet-raglia F. Metformin treatment is effective in obese teenage girls with PCOS. Hum Reprod 2006;21:2252-2256.
258. Ibanez L, Valls C, Marcos MV, Ong K, Dunger DB, De Zegher F. Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: Effects of prepubertal initiation and postpubertal discon¬tinuation of metformin treatment. J Clin Endocrinol Metab 2004;89:4331-4337.
259. Spiegelman BM. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-514.
260. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000;405:421-424.
261. Hasegawa I, Murakawa H, Suzuki M, Yamamoto Y, Kur-abayashi T, Tanaka K. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resis¬tance-related polycystic ovary syndrome. Fertil Steril 1999; 71:323-327.
262. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanely R, Fereshetian AG, O'Keefe M, Ghzaai MN, Group. PTS. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001;86: 1626-1632.
263. Azziz R, Ehrmann D, Legro R, Fereshetian A, O'Keefe M, Ghazzi MN, PCOS/Troglitazone Study Group. Troglita-zone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril 2003;79:932-937.
264. Ortega-GonzalezC,LunaS,HernandezL,CrespoG,Aguayo P, Arteaga-Troncoso G, Parra A. Responses of serum an-drogen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1360-1365.
265. Prelevic GM, Wurzburger MI, Balint-Peric L, Hardiman P, Okolo S, Maletic D, Ginsburg J. Effects of the somatostatin analogue, octreotide, in polycystic ovary syndrome. Meta¬bolism 1992;41:76-79.
266. Prelevic GM, Wurzburger MI, Balint-Peric L, Nesic JS. Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syn¬drome. Lancet 1990;336:900-903.
267. Fulghesu AM, Lanzone A, Andreani CL, Pierro E, Caruso A, Mancuso S. Effectiveness of a somatostatin analogue in lowering luteinizing hormone and insulin-stimulated se¬cretion in hyperinsulinemic women with polycystic ovary disease. Fertil Steril 1995;64:703-708.
268. Hsu WH, Xiang HD, Rajan AS, Kunze DL, Boyd AE, 3rd. Somatostatin inhibits insulin secretion by a G-protein-mediated decrease in Ca2\+ entry through voltage-dependent Ca2\+ channels in the beta cell. J Biol Chem 1991;266: 837-843.
269. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:77-79.
270. Chiodera P, Volpi R, d'Amato L, Fatone M, Cigarini C, Fava A, Caiazza A, Rossi G, Coiro V. Inhibition by so-matostatin of LH-RH-induced LH release in normal men¬struating women. Gynecol Obstet Invest 1986;22:17-21.
271. Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab 2008;93: 4299-4306.
272. Ibanez L, de Zegher F. Ethinylestradiol-drospirenone, flu-tamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: Opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 2004;89:1592-1597.
273. Ibanez L, Valls C, Cabre S, De Zegher F. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hy-perandrogenism: The key role of early, low-dose flutamide. J Clin Endocrinol Metab 2004;89:4716-4720.
274. Ibanez L, de Zegher F. Flutamide-metformin plus ethiny-lestradiol- drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. J Clin Endocrinol Metab 2005;90:39-43.